The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to provide a significant substantial reduct